| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 31.25% | Wells Fargo | $550 → $525 | Maintains | Overweight |
| 08/04/2023 | 31% | RBC Capital | $522 → $524 | Maintains | Outperform |
| 08/04/2023 | 37.5% | Credit Suisse | $580 → $550 | Maintains | Outperform |
| 06/16/2023 | 37.5% | Wells Fargo | → $550 | Initiates Coverage On | → Overweight |
| 05/08/2023 | 31.25% | Citigroup | $550 → $525 | Maintains | Buy |
| 05/08/2023 | 32.75% | RBC Capital | $582 → $531 | Maintains | Outperform |
| 05/05/2023 | 45% | Credit Suisse | $680 → $580 | Maintains | Outperform |
| 02/17/2023 | 44.75% | RBC Capital | $571 → $579 | Maintains | Outperform |
| 02/17/2023 | 70% | Credit Suisse | $640 → $680 | Maintains | Outperform |
| 12/07/2022 | 41.25% | RBC Capital | → $565 | Initiates Coverage On | → Outperform |
| 10/28/2022 | 60% | Credit Suisse | $715 → $640 | Maintains | Outperform |
| 08/25/2022 | 78.75% | Credit Suisse | → $715 | Initiates Coverage On | → Outperform |
| 07/08/2022 | 75% | Citigroup | $750 → $700 | Maintains | Buy |
| 07/30/2021 | 132.5% | Wells Fargo | $735 → $930 | Maintains | Overweight |
| 02/12/2021 | 87.5% | Citigroup | $675 → $750 | Maintains | Buy |
| 02/05/2021 | 81.25% | Jefferies | $660 → $725 | Maintains | Buy |
| 07/31/2020 | 56.25% | Citigroup | $525 → $625 | Maintains | Buy |
| 05/21/2020 | 31.25% | Wells Fargo | $495 → $525 | Maintains | Overweight |
| 05/07/2020 | 31.25% | Citigroup | $480 → $525 | Maintains | Buy |
| 04/20/2020 | 20% | Citigroup | $425 → $480 | Maintains | Buy |
| 03/30/2020 | -3.75% | Wells Fargo | $440 → $385 | Maintains | Overweight |
| 03/26/2020 | 7.5% | Barclays | $435 → $430 | Maintains | Overweight |
| 03/20/2020 | 6.25% | Citigroup | $450 → $425 | Maintains | Buy |
| 02/14/2020 | 10% | Wells Fargo | $430 → $440 | Maintains | Overweight |
| 01/08/2020 | 7.5% | Wells Fargo | → $430 | Initiates Coverage On | → Overweight |
| 01/07/2020 | 12.5% | Citigroup | → $450 | Initiates Coverage On | → Buy |
| 08/20/2019 | 0% | Goldman Sachs | → $400 | Upgrades | Buy → Conviction Buy |
| 05/09/2019 | -6.25% | Deutsche Bank | $350 → $375 | Maintains | Buy |
| 05/09/2019 | -12.5% | Barclays | $340 → $350 | Maintains | Overweight |
| 03/01/2019 | -12.5% | Deutsche Bank | $330 → $350 | Maintains | Buy |
| 03/01/2019 | -15% | Barclays | $315 → $340 | Maintains | Overweight |
| 01/03/2019 | -21.25% | Barclays | → $315 | Upgrades | Equal-Weight → Overweight |
| 11/02/2018 | -21.25% | Barclays | $345 → $315 | Maintains | Equal-Weight |
| 10/17/2018 | -12.5% | Goldman Sachs | → $350 | Initiates Coverage On | → Buy |
| 09/20/2018 | -16.25% | Morgan Stanley | → $335 | Initiates Coverage On | → Equal-Weight |
| 09/05/2018 | -13.75% | Barclays | → $345 | Initiates Coverage On | → Equal-Weight |
| 08/08/2018 | -11.25% | Jefferies | $325 → $355 | Maintains | Buy |
What is the target price for Bio-Rad Laboratories (BIO)?
The latest price target for Bio-Rad Laboratories (NYSE: BIO) was reported by Wells Fargo on August 7, 2023. The analyst firm set a price target for $525.00 expecting BIO to rise to within 12 months (a possible 31.25% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Rad Laboratories (BIO)?
The latest analyst rating for Bio-Rad Laboratories (NYSE: BIO) was provided by Wells Fargo, and Bio-Rad Laboratories maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Bio-Rad Laboratories (BIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
Is the Analyst Rating Bio-Rad Laboratories (BIO) correct?
While ratings are subjective and will change, the latest Bio-Rad Laboratories (BIO) rating was a maintained with a price target of $550.00 to $525.00. The current price Bio-Rad Laboratories (BIO) is trading at is $400.00, which is out of the analyst's predicted range.